Date | Price Target | Rating | Analyst |
---|---|---|---|
7/19/2023 | $0.50 | Underperform | Jefferies |
8/19/2021 | $6.00 | Buy | HC Wainwright & Co. |
Gainers Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. Calidi Biotherapeutics (AME
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)
SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)
Jefferies initiated coverage of Senseonics with a rating of Underperform and set a new price target of $0.50
HC Wainwright & Co. initiated coverage of Senseonics Holdings with a rating of Buy and set a new price target of $6.00
SVB Leerink downgraded Senseonics Holdings from Outperform to Market Perform and set a new price target of $3.00
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
4 - Senseonics Holdings, Inc. (0001616543) (Issuer)
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM's for minimal life disruption Launch expected early in the fourth quarter of 2024 GERMANTOWN, Md. and PARSIPPANY, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the U.S. Food
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, being held in New York, NY. Management is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET and will hold one-on-one meetings. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" secti
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights & Accomplishments: Generated revenue of $4.9 million in the second quarter of 2024, representing growth of more than 18% compared to the prior year period FDA review of the 510(k) submission for the next-generation 365-day Eversense® system and operational readiness activities continue to advance for planned fourth quarter 2024 product launch Continued to advance the collaboration
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights & Accomplishments: Generated revenue of $4.9 million in the second quarter of 2024, representing growth of more than 18% compared to the prior year period FDA review of the 510(k) submission for the next-generation 365-day Eversense® system and operational readiness activities continue to advance for planned fourth quarter 2024 product launch Continued to advance the collaboration
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Management will hold a conference call to review the Company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events &
Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2024. Recent Highlights & Accomplishments: Generated revenue of $5.1 million in the first quarter of 2024, representing growth of 22% compared to the prior year period Announced integration of Eversense® CGM and the Eversense Remote Patient Monitoring (RPM) solution within St. Louis-based Mercy health care system, a major healthcare provider serving three million patients annually, including 30,000 potential CGM u
10-Q - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)
8-K - Senseonics Holdings, Inc. (0001616543) (Filer)